PRAX-222 is under clinical development by Praxis Precision Medicines and currently in Phase II for Epileptic Encephalopathy. According to GlobalData, Phase II drugs for Epileptic Encephalopathy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PRAX-222 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PRAX-222 overview

RC-222 is under development for the treatment of epileptic encephalopathy (SCN2A-DEE). The drug candidate is administered through intrathecal route and acts by targeting sodium channel protein type 2 subunit alpha (SCN2A). It is developed based on SOLIDUS antisense oligonucleotide (ASO) platform.

It was also under development for the treatment of  other central nervous system disorders and other diseases.

Praxis Precision Medicines overview

Praxis Precision Medicines (Praxis) is a clinical-stage biopharmaceutical company that translates genetic insights for the development of novel therapies to treat central nervous system disorders. The company’s pipeline program includes PRAX-114, PRAX-944, PRAXIS-050 and PRAXIS-040 which are molecule GABA receptors for the treatment of psychiatry and movement disorders. Praxis provides programs such as PRAX-562, PRAX-222, PRAX-020, SCN2A-LCF, SYNGAP1, PCDH19, and PRAXIS-030 are used for the treatment of genetic epilepsies. Praxis is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of PRAX-222’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.